Schaller Martin, Bein Matthias, Korting Hans C, Baur Stefan, Hamm Gerald, Monod Michel, Beinhauer Sabine, Hube Bernhard
Department of Dermatology and Allergology, University of Munich, Germany.
Infect Immun. 2003 Jun;71(6):3227-34. doi: 10.1128/IAI.71.6.3227-3234.2003.
Secreted aspartyl proteinases (Saps) contribute to the ability of Candida albicans to cause mucosal and disseminated infections. A model of vaginal candidiasis based on reconstituted human vaginal epithelium (RHVE) was used to study the expression and role of these C. albicans proteinases during infection and tissue damage of vaginal epithelium. Colonization of the RHVE by C. albicans SC5314 did not cause any visible epithelial damage 6 h after inoculation, although expression of SAP2, SAP9, and SAP10 was detected by reverse transcriptase PCR. However, significant epithelial damage was observed after 12 h, concomitant with the additional expression of SAP1, SAP4, and SAP5. Additional transcripts of SAP6 and SAP7 were detected at a later stage of the artificial infection (24 h). Similar SAP expression profiles were observed in three samples isolated from human patients with vaginal candidiasis. In experimental infection, secretion of antigens Sap1 to Sap6 by C. albicans was confirmed at the ultrastructural level by using polyclonal antisera raised against Sap1 to Sap6. Addition of the aspartyl proteinase inhibitors pepstatin A and the human immunodeficiency virus proteinase inhibitors ritonavir and amprenavir strongly reduced the tissue damage of the vaginal epithelia by C. albicans cells. Furthermore, SAP null mutants lacking either SAP1 or SAP2 had a drastically reduced potential to cause tissue damage even though SAP3, SAP4, and SAP7 were up-regulated in these mutants. In contrast the vaginopathic potential of mutants lacking SAP3 or SAP4 to SAP6 was not reduced compared to wild-type cells. These data provide further evidence for a crucial role of Sap1 and Sap2 in C. albicans vaginal infections.
分泌型天冬氨酸蛋白酶(Saps)有助于白色念珠菌引起黏膜感染和播散性感染。基于重组人阴道上皮(RHVE)建立的阴道念珠菌病模型,用于研究这些白色念珠菌蛋白酶在阴道上皮感染和组织损伤过程中的表达及作用。接种6小时后,白色念珠菌SC5314在RHVE上定植未引起任何可见的上皮损伤,尽管通过逆转录聚合酶链反应检测到了SAP2、SAP9和SAP10的表达。然而,12小时后观察到明显的上皮损伤,同时伴有SAP1、SAP4和SAP5的额外表达。在人工感染后期(24小时)检测到了SAP6和SAP7的额外转录本。从患有阴道念珠菌病的人类患者分离的三个样本中观察到了类似的SAP表达谱。在实验性感染中,通过使用针对Sap1至Sap6产生的多克隆抗血清,在超微结构水平证实了白色念珠菌分泌抗原Sap1至Sap6。添加天冬氨酸蛋白酶抑制剂胃蛋白酶抑制剂A以及人类免疫缺陷病毒蛋白酶抑制剂利托那韦和安普那韦,可显著减少白色念珠菌细胞对阴道上皮的组织损伤。此外,缺乏SAP1或SAP2的SAP缺失突变体导致组织损伤的潜力大幅降低,尽管在这些突变体中SAP3、SAP4和SAP7上调。相比之下,与野生型细胞相比,缺乏SAP3或SAP4至SAP6的突变体的致阴道病潜力并未降低。这些数据为Sap1和Sap2在白色念珠菌阴道感染中的关键作用提供了进一步证据。